MLH1 Antibody

Code CSB-PA003247
Size US$167
  • Western Blot analysis of Jurkat cells using MLH1 Polyclonal Antibody
  • Western Blot analysis of Jurkat cells using MLH1 Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. P40692
Target Names MLH1
Alternative Names COCA 2 antibody; COCA2 antibody; DNA mismatch repair protein Mlh1 antibody; FCC 2 antibody; FCC2 antibody; hMLH 1 antibody; hMLH1 antibody; HNPCC 2 antibody; HNPCC antibody; HNPCC2 antibody; MGC5172 antibody; MLH 1 antibody; MLH1 antibody; MLH1_HUMAN antibody; MutL homolog 1 (E. coli) antibody; MutL homolog 1 antibody; MutL homolog 1 colon cancer nonpolyposis type 2 antibody; MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibody; MutL protein homolog 1 antibody; MutL, E. coli, homolog of, 1 antibody
Raised in Rabbit
Species Reactivity Human,Mouse,Rat
Immunogen Synthesized peptide derived from the Internal region of Human MLH1.
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Isotype IgG
Purification Method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form Liquid
Tested Applications WB, IF, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IF 1:200-1:1000
ELISA 1:20000
Protocols Western Blotting(WB) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
Gene References into Functions
  1. Low MLH1 expression is associated with Colonic Adenoma and Adenocarcinoma. PMID: 29976631
  2. Single-Nucleotide Polymorphisms of the MLH1 is associated with Basal Cell Carcinoma. PMID: 28667494
  3. this meta-analysis suggested that hMLH1 methylation was associated with an increased CRC risk. PMID: 29970664
  4. The DNA mismatch repair gene (MMR) plays an important role in anti-carcinogenesis and MMR gene deficiency. PMID: 29728922
  5. Study investigated the counteraction of oxidative stress by vitamin E in the colorectal cancer cell line Caco-2 under normal and high glucose cell culture condition. Gene expression and promoter methylation of the DNA repair gene MutL homolog 1 (MLH1) and the DNA methyltransferase 1 (DNMT1) were investigated. Induction of MLH1 and DNMT1 gene expression was noticed, accompanied by an increase in global methylation. PMID: 29854080
  6. the results identified for the first time a MLH1 missense mutation (NM_000249.3:p.Tyr379Ser/c.1136A>C) in a Chinese family with Gardner syndrome (GS), thus broadening the range of mutated genes associated with GS. PMID: 29845239
  7. This study demonstrated that Aberrant methylation of mutL homolog 1 is associated with increased risk of non-small cell lung cancer PMID: 29205508
  8. MLH1's ATPase domain has a crucial role in preventing the aberrant formation of telomeric sequences at the intra-chromosomal regions and preserving genome stability. PMID: 29544212
  9. provide evidence that four of the alterations in MLH1 are causative for Lynch syndrome, four are likely neutral and one shows compromised activity which can currently not be classified with respect to its pathogenic potential PMID: 29520894
  10. This pilot study indicates oligozoospermic patients have more methylation of MLH1 than normozoospermic patients. PMID: 28983945
  11. MLH1 and PMS2 can be imported to the nucleus by a classical nuclear import pathway PMID: 29175432
  12. The MLH1-93 AA genotype is significantly associated with promoter hypermethylation and MLH1 loss in the context of Sessile serrated adenoma of dysplasia. BRAF mutant microsatellite stable colorectal cancers with the AA genotype most likely arise in traditional serrated adenomas since the A allele does not predispose to methylation in this context. PMID: 29304767
  13. Cancer developed more often in mutation carriers, with no consistent difference between MLH1 and MSH2 carriers. More polyps (mostly adenomas) were detected in MLH1 carriers. The majority (13 of 21) of malignant tumours occurred in organs for which there is no recommended surveillance, and were lethal in three patients. PMID: 29025352
  14. Data suggest that the concurrent mutations of the adenomatous polyposis coli protein (APC) and mutL protein homolog 1 (MLH1) genes probably underline the familial adenomatous polyposis (FAP) in the pedigree. PMID: 29419868
  15. Among 13 gastric tumors showing no hMLH1 or hMSH2 expression, 8 MSI-H (high) and 5 MSI-L (low) were identified. PMID: 28525661
  16. Results show that folate concentrations >45.3 nmol/L increased the risk of methylation in specific CpG sites of MLH1. PMID: 28748002
  17. In contrast to colorectal carcinoma, sporadic MLH1 deficiency is not seen in small bowel adenocarcinoma PMID: 27258561
  18. MLH1 methylation is associated with colorectal cancer. PMID: 28730335
  19. We found no correlation between the DLEC1, TUSC4 and MLH1 gene expression and NSCLC patient characteristics (gender, age and smoking) or cancer histopathology. No significant differences in the gene expression among NSCLC subtypes indicate the weakness of DLEC1, TUSC4 and MLH1 expression analysis as potential differentiating markers of NSCLC subtypes in the Polish population. PMID: 28674222
  20. The results of this meta-analysis show a significant association between hMLH1 hypermethylation and colorectal cancer risk. PMID: 28635682
  21. study to estimate frequency of point mutations and chromosomal rearrangements in 3 mismatch repair (MMR) genes MLH1, MSH2, and MSH6 among unselected patients with ovarian cancer; estimate that approximately 0.6% of unselected ovarian cancer patients have mutations in the MMR genes PMID: 28176205
  22. CpG island methylator phenotype (CIMP)+/MLH1-unmethylated (MLH1-U) tumors exhibit aggressive features and are associated with poor clinical outcomes. PMID: 27880934
  23. Analysis of expression Quantitative Trait Loci (eQTLs) provides modest support for altered regulation of MLH1 and LRRFIP2, raising the possibility that the modifier affects regulation of both genes. PMID: 28934397
  24. MLH1 deficiency had an impact on the evolution of the tumor after surgical resection in a murine xenograft model. PMID: 28512763
  25. Results indicate that the normal tissue types tested (colorectum and PBMC) experience dynamic genotype-associated epigenetic alterations at the MLH1 shore, whereas cancer tumor DNA incurs aberrant hypermethylation compared to normal DNA. These results reveal that the epigenetic landscape of MLH1 is dynamically regulated at least in part by the static genetic sequence. PMID: 28293327
  26. MLH1-methylated CpG island methylator phenotype is associated with serrated adenoma in colorectal carcinoma. PMID: 26883113
  27. cancer-specific survival did not differ in Lynch syndrome-associated colorectal cancer (CRC) compared with MLH1-hm CRC, suggesting that they carry a similar prognosis. PMID: 26866578
  28. Data show that MLH1(L749P) and MLH1(Y750X) make PMS2 prone to calyculin induced degradation, suggeting that the specific degradation of PMS2 may represent a new mechanism to regulate MLH1-PMS2 heterodimer protein MutLalpha. PMID: 28767177
  29. hMLH1 (rs1800734) AA genotype is associated with increased risk of lung cancer development. PMID: 26987333
  30. miR-148b mimic sensitized A549 xenografts to irradiation in vivo Our study demonstrated that miR-148b regulates radioresistance of lung cancer cells by modulating MLH1 expression level. miR-148b may represent a new therapeutic target for the intervention of lung cancer. PMID: 26759383
  31. hMLH1 promoter hypermethylation plays important roles in esophageal carcinoma drug-resistance PMID: 26782688
  32. Loss of MLH1 expression is associated with colorectal carcinoma. PMID: 28651545
  33. the MLH1 c.543C>T silent mutation is considered 'pathogenic'. PMID: 28334867
  34. Promoter methylation and loss of protein expression of hMLH1 are not parallel processes that occur concurrently. hMLH1 methylation is an early molecular event which occurs even in hyperplastic polyps (HPs). the loss of hMLH1 protein expression does not necessarily precede the development of cytological dysplasia in sessile serrated lesion (SSL). PMID: 26713412
  35. Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I-II colon cancer PMID: 28411881
  36. MLH1, a key protein involved in mismatch repair (MMR), suppresses telomeric sequence insertion (TSI) at intra-chromosomal regions. The frequency of TSI can be elevated by double-strand break (DSB) inducer and abolished by ATM/ATR inhibition. Suppression of TSI requires MLH1 recruitment to DSBs, indicating that MLH1's role in DSB response/repair is important for suppressing TSI. PMID: 28180301
  37. MLH1 mutations contribute to colorectal cancer susceptibility in Algerian families with suspected Lynch syndrome. PMID: 27468915
  38. MLH1 methylation analysis defines a subset of tumors that have worse prognostic features including higher tumor volume and lymph node involvement. PMID: 28709704
  39. High MLH1 expression is associated with the development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. PMID: 27803051
  40. In path_MLHI 10-year survival was 80%, relative incidence of subsequent cancer compared with incidence of first cancer was slightly but insignificantly higher than cancer incidence in patients with Lynch syndrome without previous cancer. PMID: 27261338
  41. MLH1 methylation is a frequent molecular event in colorectal cancer and lung cancer patients PMID: 28214209
  42. Both the mTOR/p-mTOR and BNIP3/Beclin-1 signaling pathways were found to be related to HRS, but only mTOR/p-mTOR is involved in the regulation of HRS via MLH1 and autophagy. PMID: 28117625
  43. Data suggest that yeast Mlh1-Mlh3 heterodimer does not exhibit hallmarks of a canonical (structure-selective) Holliday junction resolvase/endonuclease; multiple Mlh1-Mlh3 heterodimers appear to load onto DNA to form an activated polymer that cleaves DNA; human MLH1-PMS2 exhibits similar characteristics. (MLH = mutL homolog protein; PMS2 = post meiotic segregation increased 2 protein) PMID: 28453523
  44. Genetic changes between MLH1 and MSH2 were significantly positively correlated (p = 0.032). We also noted a positive correlation between genetic changes of MSH2 and DVL3 genes (p = 0.034). PMID: 28705114
  45. Mismatch repair (MMR)-deficient endometrial carcinomas have significantly increased tumoral and immune stromal PD-L1 expression relative to MMR-intact carcinomas. PD-L1 is frequently positive in both tumoral and immune cells at the periphery of MMR-deficient tumors. Lynch syndrome-associated tumors are more likely to express PDL1 relative to sporadic MLH1 promoter hypermethylation carcinomas. PMID: 27984238
  46. These results demonstrate the role of variant rs1800734 in altering transcription factor binding as well as epigenetics at regions beyond the MLH1 CpG island in which it is located. PMID: 28304185
  47. There were a 61.7% (95/154) overexpression of DNMT3B, 50.0% (77/154) loss of PTEN expression and 18.2% (28/154) loss of hMLH1 expression in endometrial carcinomas. PMID: 28220037
  48. demonstrates that lower level of histone acetylation and specific histone methylation such as H3K36me3 correlate with aberrant transcripts in hMLH1 exon 10-11 region PMID: 28381181
  49. revealed high frequencies of gene promoter methylation in NSCLCs: 84 % for DLEC1 and MLH1 and 57 % for ITGA9 PMID: 27287342
  50. In colorectal neoplasms, negative expression of the MMR proteins MLH1, MSH2 or MSH6 was seen in 15% (47 of 313) of the patients. Defect MLH1 was most common and detected in 12% of the cases. Defect MLH1 and MSH2 were identified in each patient's normal adjacent mucosa. PMID: 27836416

Show More

Hide All

Involvement in disease Hereditary non-polyposis colorectal cancer 2 (HNPCC2); Mismatch repair cancer syndrome (MMRCS); Muir-Torre syndrome (MRTES); Endometrial cancer (ENDMC); Colorectal cancer (CRC)
Subcellular Location Nucleus
Protein Families DNA mismatch repair MutL/HexB family
Tissue Specificity Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
Database Links

HGNC: 7127

OMIM: 114500

KEGG: hsa:4292

STRING: 9606.ENSP00000231790

UniGene: Hs.195364


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1